HomeCompareOLYMY vs EQR

OLYMY vs EQR: Dividend Comparison 2026

OLYMY yields 1.49% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OLYMY wins by $19.36M in total portfolio value· pulled ahead in Year 4
10 years
OLYMY
OLYMY
● Live price
1.49%
Share price
$9.37
Annual div
$0.14
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.41M
Annual income
$17,198,899.56
Full OLYMY calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — OLYMY vs EQR

📍 OLYMY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOLYMYEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OLYMY + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OLYMY pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OLYMY
Annual income on $10K today (after 15% tax)
$127.00/yr
After 10yr DRIP, annual income (after tax)
$14,619,064.63/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, OLYMY beats the other by $14,614,410.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OLYMY + EQR for your $10,000?

OLYMY: 50%EQR: 50%
100% EQR50/50100% OLYMY
Portfolio after 10yr
$9.73M
Annual income
$8,602,187.58/yr
Blended yield
88.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

OLYMY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.3
Piotroski
7/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OLYMY buys
0
EQR buys
0
No recent congressional trades found for OLYMY or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOLYMYEQR
Forward yield1.49%5.87%
Annual dividend / share$0.14$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%15.8%
Portfolio after 10y$19.41M$47.8K
Annual income after 10y$17,198,899.56$5,475.61
Total dividends collected$19.21M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: OLYMY vs EQR ($10,000, DRIP)

YearOLYMY PortfolioOLYMY Income/yrEQR PortfolioEQR Income/yrGap
1$10,999$298.83$11,380$679.82$381.00EQR
2$12,383$614.34$13,014$837.25$631.00EQR
3$14,543$1,292.83$14,961$1,036.20$418.00EQR
4← crossover$18,399$2,837.94$17,297$1,289.22+$1.1KOLYMY
5$26,398$6,711.03$20,121$1,613.15+$6.3KOLYMY
6$46,243$17,997.57$23,561$2,030.84+$22.7KOLYMY
7$108,411$58,930.72$27,783$2,573.54+$80.6KOLYMY
8$374,234$258,234.50$33,013$3,284.39+$341.2KOLYMY
9$2,066,647$1,666,216.42$39,547$4,223.51+$2.03MOLYMY
10$19,410,212$17,198,899.56$47,791$5,475.61+$19.36MOLYMY

OLYMY vs EQR: Complete Analysis 2026

OLYMYStock

Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company offers gastrointestinal endoscopy system products comprising video endoscopy and ultrasound systems; GI endotherapy products consisting of CRC devices and HPB devices/hemostasis products; endoscopic solutions ecosystem products, including intelligent ecosystem operating software platforms, and AI insights and computer-aided detection/diagnosis products; reprocessing products, such as endoscope reprocessors, chemicals, accessories, and peripherals; and medical services, which include repair center services. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat; and gastroenterology devices and gynecology products. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.

Full OLYMY Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this OLYMY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OLYMY vs SCHDOLYMY vs JEPIOLYMY vs OOLYMY vs KOOLYMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.